argenx SE | ARGX - Ebitda

Stock Price
648.40
Daily Change
8.60 1.34%
Monthly
17.21%
Yearly
29.97%
Q3 Forecast
635.71

argenx SE reported $288.02M in EBITDA for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 7.18B
Cash and Equivalent USD 2.09B
Cost of Sales USD 110.75M
Current Assets USD 5.83B
Current Liabilities USD 1.04B
Debt USD 43.15M
Dividend Yield USD 0
EBIT USD 288.03M
EBITDA USD 288.03M
Employees USD 1.15K
EPS Earnings Per Share USD 3.26
Equity Capital and Reserves USD 6.1B
Gross Profit on Sales USD 837.21M
Interest Expense on Debt USD 1.13M
Interest Income USD 38.4M
Loan Capital USD 35.57M
Market Capitalization USD 38.78B
Net Income USD 245.36M
Operating Expenses USD 744.12M
Operating Profit USD 203.84M
Ordinary Share Capital USD 61.17M
PE Price to Earnings USD 33.59
Pre-Tax Profit USD 286.9M
Sales Revenues USD 842.5M
Selling and Administration Expenses USD 321.35M
Stock USD 340.62M
Trade Creditors USD 852.2M
Trade Debtors USD 1.2B

Ebitda Change Date
AstraZeneca USD 4.96B 127M Jun/2025
Galapagos EUR -158708000 177.84M Mar/2025
Genmab DKK 376M 172M Jun/2025
GlaxoSmithKline GBP 3.18B 45M Jun/2025
GRIFOLS EUR 347.24M 58.35M Jun/2025
Hikma Pharmaceutical USD 369M 84M Dec/2024
Qiagen NV USD 208.98M 38.23M Jun/2025
UCB EUR 1.37B 715M Dec/2024